Automated glaucoma screening from optical coherence tomography (OCT) faces two persistent challenges: scarcity of expert-labeled data and unreliable model predictions on diagnostically ambiguous cases. We present a two-tier diagnostic pipeline that addresses both. In the first tier, an EfficientNetV2-S classifier trained under a semi-supervised pseudo supervisor framework achieves 0.84 AUC on 150 held-out test patients from the Harvard Glaucoma Detection and Progression dataset, using only 350 labeled training samples out of 700. In the second tier, 124 flagged cases are routed to a multi-agent system built on MedGemma 4B, where three specialist agents deliberate over three rounds before rendering a final diagnosis. On these flagged cases, the agent system achieves 100% sensitivity—detecting all 55 glaucoma cases with zero missed diagnoses—and 89.5% overall accuracy (111/124), compared to the classifier’s 73.4% (91/124). Uncertainty analysis confirms that the classifier’s output probability reliably separates confident predictions (96.3% accuracy, n = 27) from uncertain ones (74.0%, n = 123), producing a 22-percentage-point gap that serves as a triage signal. The agents fix 32 cases the classifier misclassifies while introducing 12 new errors, yielding a net improvement of 20 cases. These results are from a single training run without variance estimates and should be interpreted as preliminary evidence that uncertainty-gated routing to vision-language model agents can meaningfully improve diagnostic accuracy on the cases where automated classifiers are least reliable.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study uses a publicly available, de-identified dataset (Harvard Glaucoma Detection and Progression dataset). No new data were collected and no identifiable human subjects were involved. https://ophai.hms.harvard.edu/code/harvard-gdp/

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes